By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Biomerica, Inc.

Biomerica, Inc. (BMRA)

NASDAQ Currency in USD
$2.95
+$0.02
+0.68%
Last Update: 11 Sept 2025, 20:00
$7.51M
Market Cap
-10.60
P/E Ratio (TTM)
Forward Dividend Yield
$2.08 - $10.16
52 Week Range

BMRA Stock Price Chart

Explore Biomerica, Inc. interactive price chart. Choose custom timeframes to analyze BMRA price movements and trends.

BMRA Company Profile

Discover essential business fundamentals and corporate details for Biomerica, Inc. (BMRA) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Devices

IPO Date

7 Sept 1984

Employees

64.00

CEO

Zackary S. Irani

Description

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

BMRA Financial Timeline

Browse a chronological timeline of Biomerica, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 Apr 2026

Upcoming earnings on 12 Jan 2026

Upcoming earnings on 21 Oct 2025

Earnings released on 29 Aug 2025

EPS came in at -$0.16 , while revenue for the quarter reached $749.00K .

Stock split effective on 21 Apr 2025

Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 14 Apr 2025

EPS came in at -$0.48 , while revenue for the quarter reached $1.12M .

Earnings released on 14 Jan 2025

EPS came in at -$0.06 , while revenue for the quarter reached $1.64M .

Earnings released on 15 Oct 2024

EPS came in at -$0.08 , while revenue for the quarter reached $1.81M .

Earnings released on 28 Aug 2024

EPS came in at -$0.09 , while revenue for the quarter reached $1.12M .

Earnings released on 12 Apr 2024

EPS came in at -$0.11 , while revenue for the quarter reached $1.02M .

Earnings released on 16 Jan 2024

EPS came in at -$0.09 , while revenue for the quarter reached $1.57M .

Earnings released on 12 Oct 2023

EPS came in at -$0.07 , while revenue for the quarter reached $1.71M , missing expectations by -93.56%.

Earnings released on 25 Aug 2023

EPS came in at -$0.10 falling short of the estimated $0.04 by -350.00%, while revenue for the quarter reached $1.11M , missing expectations by -85.61%.

Earnings released on 14 Apr 2023

EPS came in at -$0.12 falling short of the estimated $0.02 by -700.00%, while revenue for the quarter reached $1.11M , missing expectations by -85.57%.

Earnings released on 13 Jan 2023

EPS came in at -$0.12 , while revenue for the quarter reached $1.48M , missing expectations by -47.07%.

Earnings released on 13 Oct 2022

EPS came in at -$0.16 falling short of the estimated -$0.02 by -700.00%, while revenue for the quarter reached $1.64M , missing expectations by -39.35%.

Earnings released on 29 Aug 2022

EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $5.30M , beating expectations by +146.96%.

Earnings released on 14 Apr 2022

EPS came in at -$0.01 surpassing the estimated -$0.10 by +90.00%, while revenue for the quarter reached $7.66M , beating expectations by +164.43%.

Earnings released on 12 Jan 2022

EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $4.65M , beating expectations by +60.24%.

Earnings released on 14 Oct 2021

EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $1.26M , missing expectations by -29.90%.

Earnings released on 27 Aug 2021

EPS came in at -$0.12 falling short of the estimated -$0.10 by -20.00%, while revenue for the quarter reached $1.05M .

Earnings released on 14 Apr 2021

EPS came in at -$0.15 falling short of the estimated -$0.08 by -87.50%, while revenue for the quarter reached $3.63M , beating expectations by +43.66%.

Earnings released on 14 Jan 2021

EPS came in at -$0.13 falling short of the estimated -$0.10 by -30.00%, while revenue for the quarter reached $1.37M , missing expectations by -26.21%.

Earnings released on 15 Oct 2020

EPS came in at -$0.14 falling short of the estimated -$0.09 by -55.56%, while revenue for the quarter reached $1.14M , beating expectations by +7.74%.

BMRA Stock Performance

Access detailed BMRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run